AIMS
Tedisamil is a new blocker of K+ currents in cardiac tissues, exerts bradycardic effects and has shown clinical efficacy in angina pectoris. Theoretically, when coadministered with a beta-adrenoceptor blocker the tedisamil combination could induce dangerous bradycardia and QT interval prolongation. Therefore, the aim of this study was to evaluate the effects of tedisamil and atenolol alone and in combination, on heart rate and QT interval duration at rest and during exercise tests.
METHODS
The effects of tedisamil (100 mg twice daily) and atenolol (50 mg twice daily) on heart rate and QT interval duration were analysed in a three-period crossover study in healthy male volunteers.
RESULTS
This study showed that tedisamil exerted a significant (P<0.05) bradycardic action at rest (-10 beats min(-1); 95% CI: -6 to -15 beats min(-1)) similar to atenolol (-14 beats min(-1); -11 to -17) and drug combination (-9 beats min(-1); -6 to -12). During exercise, at the highest comparable workload, heart rate did not decrease significantly with tedisamil but decreased significantly with atenolol (-42 beats min(-1); -37 to -47) and combination (-47 beats min(-1); -41 to 52). Atenolol did not modify QT interval duration. Tedisamil alone and in combination with atenolol increased QT interval duration by 12% (95% CI: 7 to 17%) and 12% (8 to 16) respectively at RR=1000 ms, but not at RR<700 ms (combination). Tedisamil alone and in combination induced a reverse rate-dependent QT interval prolongation.
CONCLUSIONS
These results indicate that the combination of tedisamil and atenolol is not associated with excessive bradycardia or excessive QT interval prolongation in healthy subjects.
[1]
C. Funck-Brentano,et al.
Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans.
,
1996,
Circulation.
[2]
M. Schlepper,et al.
Tedisamil (KC 8857) is a new specific bradycardic drug: does it also influence myocardial contractility? Analysis by the conductance (volume) technique in coronary artery disease.
,
1993,
American heart journal.
[3]
A. Wellstein,et al.
d‐Sotalol reduces heart rate in vivo through a β‐adrenergic receptor–independent mechanism
,
1993,
Clinical pharmacology and therapeutics.
[4]
C. Benedict.
The QT Interval and Drug-Associated Torsades de Pointes
,
1993
.
[5]
M. Curtis,et al.
Influence of Tedisamil on the Initiation and Maintenance of Ventricular Fibrillation: Chemical Defibrillation by Ito Blockade?
,
1991,
Journal of cardiovascular pharmacology.
[6]
B. Singh,et al.
When is QT prolongation antiarrhythmic and when is it proarrhythmic?
,
1989,
The American journal of cardiology.
[7]
J. Weirich,et al.
Electrophysiological profile of KC 8857, a new bradycardic agent
,
1987
.